Within the battle between weight-loss drug firms, Eli Lilly has emerged because the clear winner for traders. The maker of Zepbound and diabetes remedy Mounjaro hit a $1 trillion market cap on Friday, making it the primary health-care firm to interrupt by way of the mark. Novo Nordisk , alternatively, noticed shares tumble 6% on Monday after its Alzheimer’s trial failed to satisfy its predominant objective. The trial studied whether or not semaglutide, the energetic ingredient in its diabetes and weight reduction medicine Ozempic and Wegovy, helped gradual the progress of the illness. For a lot of on Wall Avenue, the sell-off wasn’t stunning and did not essentially present a shopping for alternative. Evan Seigerman, BMO Capital Markets analyst, stated he prefers Eli Lilly over Novo Nordisk, although the latter’s sell-off could also be overdone. Eli Lilly is rather more diversified than Novo Nordisk and is a stronger participant in weight problems, he stated. “There’s all the time concern round what does the trillion greenback market cap imply for Lilly, and is that one thing to fret about,” he stated. “Essentially, it highlights actual confidence within the longevity of, not simply their metabolic companies, however all the companies that they run.” Seigerman expects Eli Lilly’s experimental oral GLP-1 , orforglipron, to see good utilization when it hits the market subsequent yr as a result of he stated it has a greater profile than Novo Nordisk’s oral model of Wegovy . Whereas the previous does not get as a lot weight reduction, it does not should be timed with consuming or consuming , he famous. “Oral Wegovy,” alternatively, needs to be taken within the morning half-hour earlier than consuming or consuming, he stated. LLY YTD mountain Eli Lilly yr up to now Novo’s oral GLP-1 is at the moment underneath evaluation with the Meals and Drug Administration. Lilly stated it plans to submit orforglipron for approval for weight problems or obese remedy in 2025 and for kind 2 diabetes in 2026. Seigerman has outperform score on Eli Lilly and a market carry out score on Novo Nordisk. In the meantime, Jefferies believes some traders had stayed in Novo Nordisk on the hopes, albeit not excessive, for a constructive end result within the Alzheimer’s trial and the sell-off was merely these traders exiting the inventory. “With top-line dynamics for 2026-2027E nonetheless closely underneath debate, we imagine it’s unlikely traders will rush again into the title, and additional a number of compression doable because the sema 2031/32E patent expiry looms,” Jefferies’ analyst Michael Leuchten stated in a word Monday. Leuchten has an underperform score on Novo Nordisk inventory. NVO YTD mountain Novo Nordisk yr up to now Morgan Stanley additionally stated the set-up from right here stays difficult for Novo Nordisk. The agency, which stays underweight on the inventory, sees restricted scope for development in 2026. Novo Nordisk additionally has a narrowing window to function forward of a serious lack of exclusivity of semaglutide in 2031/2032, analyst Thibault Boutherin stated in a word Monday. The Alzheimer’s trial outcomes have been sufficient to make HSBC downgrade Novo Nordisk to carry from purchase on Monday. Even when the trial had not succeeded however nonetheless confirmed an enchancment in cognitive decline, lots of people would have used it off label, analyst Rajesh Kumar informed CNBC. “The fact is, they’ve had a large alternative to be a market chief,” he stated. “They’ve tousled on execution.” Eli Lilly catalysts forward On the similar time, traders stay bullish on Eli Lilly whilst its valuation strikes increased. The inventory hit a 52-week excessive on Monday. Morgan Stanley is amongst these on Wall Avenue who anticipate continued share features. On Sunday, the agency raised its worth goal on the inventory to $1,290 from $1,171, suggesting greater than 10% upside from Friday’s shut. “LLY has essentially the most strong new product cycle (and therefore development) outlook in Pharma as the corporate may launch further three new medicine over the subsequent three years in a big finish market of diabesity,” analyst Terence Flynn stated in a word to purchasers. The agency’s survey of main care suppliers initiatives ongoing GLP-1 market development for weight problems and diabetes, with Eli Lilly persevering with to achieve share over Novo Nordisk, he famous. As well as, the survey means that Eli Lilly’s experimental oral GLP-1 may signify 30% of the corporate’s whole GLP-1 combine a yr after launch. Bernstein additionally raised its worth goal on Eli Lilly Monday to $1,300 from $1,100, implying almost 23% upside from Friday’s shut. The inventory is now “beat-and-raise Orfo launch story,” stated analyst Courtney Breen. “There may be an extremely wealthy catalyst path forward … nevertheless essentially the most significant inventory strikes might be tied to script tendencies and income realization in 2026,” she wrote in a word to purchasers. “We see a straightforward beat to consensus expectations for Orforglipron, with our conservative ’26 estimates of $1.8B (80k scripts per week in oral market + US solely) far outpacing the present consensus of $550m.” Do not depend out Novo Nordisk Nonetheless, there are some who see a possibility to get into Novo Nordisk now that it has offered off. JPMorgan known as the transfer an “overreaction.” “General, whereas the failure of semaglutide to indicate a profit in Alzheimer’s does take away a possible upside driver, in actuality there’s restricted to no affect on Novo forecasts,” analyst Richard Vosser stated in a word Monday. He has an obese score on the inventory. Jared Holz, health-care strategist at Mizuho Securities America, stated the preliminary 9% drop within the inventory introduced it right down to pre-Ozempic ranges. “I do really assume it is a shopping for alternative,” he stated. “Heading into subsequent yr, I feel with a number of the pricing negotiations behind them, I feel it units as much as doubtlessly be a greater inventory in 2026.” Holz sees Novo Nordisk extra as a price inventory, whereas it might be argued El Lilly is not even in the identical peer group anymore. “For Eli Lilly, I simply assume the execution has been very strong,” he stated. “The class of those oral weight reduction drugs goes to be most likely near $50 billion, and so it is robust to get unfavorable on Lilly once they’re arrange this manner. The one factor that form of would concern me close to time period is the near-term momentum.”
